Avcioglu et al. have demonstrated that the visfatin serum level can be treated as a risk factor for endometrial cancer on a par with patient age, BMI, and diabetes mellitus type 2 [29]. This evidence concerns the gene NAMPT and type 2 diabetes mellitus.